{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:17:31Z","timestamp":1766157451636},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,3,29]],"date-time":"2011-03-29T00:00:00Z","timestamp":1301356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s10549-011-1455-9","type":"journal-article","created":{"date-parts":[[2011,3,28]],"date-time":"2011-03-28T07:09:07Z","timestamp":1301296147000},"page":"705-712","source":"Crossref","is-referenced-by-count":44,"title":["A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?"],"prefix":"10.1007","volume":"127","author":[{"given":"Meijun","family":"Long","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijuan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiannan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanyan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heran","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengtao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengxi","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,29]]},"reference":[{"issue":"7934","key":"1455_CR1","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(75)90897-1","volume":"2","author":"RM Galbraith","year":"1975","unstructured":"Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ (1975) Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2(7934):528\u2013530","journal-title":"Lancet"},{"issue":"7","key":"1455_CR2","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1001\/archinte.145.7.1313","volume":"145","author":"SN Thung","year":"1985","unstructured":"Thung SN, Gerber MA, Klion F, Gilbert H (1985) Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 145(7):1313\u20131314","journal-title":"Arch Intern Med"},{"issue":"270","key":"1455_CR3","first-page":"895","volume":"73","author":"GL Bird","year":"1989","unstructured":"Bird GL, Smith H, Portmann B, Alexander GJ, Williams R (1989) Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers. Q J Med 73(270):895\u2013902","journal-title":"Q J Med"},{"issue":"1","key":"1455_CR4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","volume":"100","author":"AS Lok","year":"1991","unstructured":"Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100(1):182\u2013188","journal-title":"Gastroenterology"},{"issue":"8\u20139","key":"1455_CR5","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/0959-8049(92)90513-2","volume":"28A","author":"LT Soh","year":"1992","unstructured":"Soh LT, Ang PT, Sng I, Chua EJ, Ong YW (1992) Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. Eur J Cancer 28A(8\u20139):1338\u20131339","journal-title":"Eur J Cancer"},{"issue":"10","key":"1455_CR6","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2210::AID-CNCR24>3.0.CO;2-0","volume":"78","author":"Y Nakamura","year":"1996","unstructured":"Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E (1996) Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987\u20131991. Cancer 78(10):2210\u20132215","journal-title":"Cancer"},{"issue":"1","key":"1455_CR7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/A:1008234807768","volume":"8","author":"K Kumagai","year":"1997","unstructured":"Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, Shimano S, Kudoh I, Nakamura H, Sawada K et al (1997) Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol 8(1):107\u2013109","journal-title":"Ann Oncol"},{"issue":"4","key":"1455_CR8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.7326\/0003-4819-96-4-447","volume":"96","author":"JH Hoofnagle","year":"1982","unstructured":"Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J (1982) Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96(4):447\u2013449","journal-title":"Ann Intern Med"},{"issue":"1","key":"1455_CR9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/sj.bjc.6690652","volume":"81","author":"CG Alexopoulos","year":"1999","unstructured":"Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G (1999) Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer 81(1):69\u201374","journal-title":"Br J Cancer"},{"issue":"3","key":"1455_CR10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","volume":"62","author":"W Yeo","year":"2000","unstructured":"Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62(3):299\u2013307","journal-title":"J Med Virol"},{"issue":"4","key":"1455_CR11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jmv.10430","volume":"70","author":"W Yeo","year":"2003","unstructured":"Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70(4):553\u2013561","journal-title":"J Med Virol"},{"issue":"6","key":"1455_CR12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1478-3231.2004.0964.x","volume":"24","author":"MS Dai","year":"2004","unstructured":"Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY (2004) Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 24(6):540\u2013546","journal-title":"Liver Int"},{"issue":"10","key":"1455_CR13","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1023\/A:1026622807373","volume":"43","author":"F ter Borg","year":"1998","unstructured":"ter Borg F, Smorenburg S, de Man RA, Rietbroek RC, Chamuleau RA, Jones EA (1998) Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy. Dig Dis Sci 43(10):2267\u20132270","journal-title":"Dig Dis Sci"},{"issue":"4","key":"1455_CR14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/A:1008206519571","volume":"9","author":"FL Clark","year":"1998","unstructured":"Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN (1998) Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin\u2019s lymphoma. Ann Oncol 9(4):385\u2013387","journal-title":"Ann Oncol"},{"issue":"3","key":"1455_CR15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<263::AID-JMV1>3.0.CO;2-X","volume":"59","author":"W Yeo","year":"1999","unstructured":"Yeo W, Steinberg JL, Tam JS, Chan PK, Leung NW, Lam KC, Mok TS, Johnson PJ (1999) Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 59(3):263\u2013269","journal-title":"J Med Virol"},{"issue":"1","key":"1455_CR16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1572-0241.1999.00808.x","volume":"94","author":"A Ahmed","year":"1999","unstructured":"Ahmed A, Keeffe EB (1999) Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 94(1):249\u2013251","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1455_CR17","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1111\/j.1572-0241.2001.03824.x","volume":"96","author":"F Cainelli","year":"2001","unstructured":"Cainelli F, Longhi MS, Concia E, Vento S (2001) Failure of lamivudine therapy for chemotherapy-induced reactivation of hepatitis B. Am J Gastroenterol 96(5):1651\u20131652","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"1455_CR18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1046\/j.1365-2141.2000.01847.x","volume":"108","author":"F Silvestri","year":"2000","unstructured":"Silvestri F, Ermacora A, Sperotto A, Patriarca F, Zaja F, Damiani D, Fanin R, Baccarani M (2000) Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation. Br J Haematol 108(2):394\u2013396","journal-title":"Br J Haematol"},{"issue":"2","key":"1455_CR19","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V99.2.724","volume":"99","author":"M Persico","year":"2002","unstructured":"Persico M, De Marino F, Russo GD, Morante A, Rotoli B, Torella R, De Renzo A (2002) Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 99(2):724\u2013725","journal-title":"Blood"},{"issue":"2","key":"1455_CR20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V100.2.391","volume":"100","author":"O Shibolet","year":"2002","unstructured":"Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R (2002) Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 100(2):391\u2013396","journal-title":"Blood"},{"issue":"1","key":"1455_CR21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1046\/j.1365-2141.2001.03099.x","volume":"115","author":"G Rossi","year":"2001","unstructured":"Rossi G, Pelizzari A, Motta M, Puoti M (2001) Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 115(1):58\u201362","journal-title":"Br J Haematol"},{"issue":"1","key":"1455_CR22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10549-005-1942-y","volume":"92","author":"MS Dai","year":"2005","unstructured":"Dai MS, Chao TY (2005) Lamivudine therapy in HBsAg-carrying breast cancer patients undergoing chemotherapy: prophylactic or preemptive? Breast Cancer Res Treat 92(1):95\u201396","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"1455_CR23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10549-004-0725-1","volume":"88","author":"W Yeo","year":"2004","unstructured":"Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, Johnson PJ (2004) Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 88(3):209\u2013215","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"1455_CR24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","volume":"148","author":"R Loomba","year":"2008","unstructured":"Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148(7):519\u2013528","journal-title":"Ann Intern Med"},{"key":"1455_CR25","doi-asserted-by":"crossref","unstructured":"Tsai SH, Dai MS, Yu JC, Ho CL, Chen YC, Wu YY, Chang PY, Kao WY, Chao TY (2010) Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine. Support Care Cancer. doi: 10.1007\/s00520-010-1019-2","DOI":"10.1007\/s00520-010-1019-2"},{"issue":"3","key":"1455_CR26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/jmv.2060","volume":"65","author":"W Yeo","year":"2001","unstructured":"Yeo W, Chan PK, Chan HL, Mo FK, Johnson PJ (2001) Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 65(3):473\u2013477","journal-title":"J Med Virol"},{"issue":"2","key":"1455_CR27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","volume":"43","author":"W Yeo","year":"2006","unstructured":"Yeo W, Johnson PJ (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43(2):209\u2013220","journal-title":"Hepatology"},{"issue":"7","key":"1455_CR28","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1365-2036.2006.03081.x","volume":"24","author":"HE Kohrt","year":"2006","unstructured":"Kohrt HE, Ouyang DL, Keeffe EB (2006) Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 24(7):1003\u20131016","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1455_CR29","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","volume":"125","author":"AS Lok","year":"2003","unstructured":"Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA et al (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125(6):1714\u20131722","journal-title":"Gastroenterology"},{"issue":"15","key":"1455_CR30","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON et al (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351(15):1521\u20131531","journal-title":"N Engl J Med"},{"issue":"1","key":"1455_CR31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","volume":"295","author":"CJ Chen","year":"2006","unstructured":"Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1):65\u201373","journal-title":"JAMA"},{"issue":"3","key":"1455_CR32","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","volume":"130","author":"UH Iloeje","year":"2006","unstructured":"Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130(3):678\u2013686","journal-title":"Gastroenterology"},{"issue":"4","key":"1455_CR33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jnci\/dji043","volume":"97","author":"MW Yu","year":"2005","unstructured":"Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, Kao JH, Chen DS, Chen CJ (2005) Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 97(4):265\u2013272","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1455_CR34","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199008023230503","volume":"323","author":"RP Perrillo","year":"1990","unstructured":"Perrillo RP, Schiff ER, Davis GL, Bodenheimer HJ, Lindsay K, Payne J, Dienstag JL, O\u2019Brien C, Tamburro C, Jacobson IM et al (1990) A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 323(5):295\u2013301","journal-title":"N Engl J Med"},{"issue":"17","key":"1455_CR35","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","volume":"341","author":"JL Dienstag","year":"1999","unstructured":"Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M et al (1999) Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341(17):1256\u20131263","journal-title":"N Engl J Med"},{"issue":"10","key":"1455_CR36","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354(10):1001\u20131010","journal-title":"N Engl J Med"},{"issue":"6","key":"1455_CR37","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","volume":"131","author":"SJ Hadziyannis","year":"2006","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J (2006) Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5\u00a0years. Gastroenterology 131(6):1743\u20131751","journal-title":"Gastroenterology"},{"issue":"9","key":"1455_CR38","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","volume":"348","author":"SJ Hadziyannis","year":"2003","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS et al (2003) Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348(9):800\u2013807","journal-title":"N Engl J Med"},{"issue":"3","key":"1455_CR39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.510240339","volume":"24","author":"R Ling","year":"1996","unstructured":"Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ (1996) Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24(3):711\u2013713","journal-title":"Hepatology"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1455-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-011-1455-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1455-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T13:16:39Z","timestamp":1560086199000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-011-1455-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,29]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["1455"],"URL":"https:\/\/doi.org\/10.1007\/s10549-011-1455-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,29]]}}}